Pregnancy outcomes after chemotherapy for trophoblastic neoplasia

Mila Trementosa Garcia¹*, Lawrence Hsu Lin¹, Koji Fushida¹, Rossana Pulcineli Vieira Francisco¹, Marcelo Zugaib¹

¹Division of Obstetrics, Department of Gynecology and Obstetrics, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP Brazil

INTRODUCTION

Gestational trophoblastic disease is a group of placental disorders that include hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor. Hydatidiform mole is the most common form of trophoblastic disease, and is considered a benign condition that may develop into other malignant forms, referred indistinctly as gestational trophoblastic neoplasia.²

The incidence of hydatidiform mole varies in different populations, affecting 1-1,000 pregnancies in Europe and the United States, while in Asian countries the incidence may reach up to two cases in every 1,000 pregnancies.² In Brazil, there is no official database for gestational trophoblastic disease. A large Brazilian epidemiological study showed the occurrence of 5,250 cases of gestational trophoblastic disease in ten reference centers over the course of 11 years, which can be translated into 477 new cases per year.³

The diagnosis of hydatidiform mole is based on clinical symptoms, serum level of human chorionic gonadotropin (hCG), ultrasound scans and histopathological analysis of the material obtained after uterine evacuation. Hydatidiform mole is characterized into complete and partial mole according to clinical, histological and genetic features. In general, complete moles are generated by the fertilization of an empty oocyte by a sperm that...
duplicates its genetic material or by two spermatozoa, giving rise to an androgenetic diploid conception with intense trophoblastic hyperplasia and diffuse hydropic villi. In contrast, the partial mole originates from dispermy, with fertilization of an oocyte by two spermatozoa, producing a triploid pregnancy, with focal histological abnormalities.¹ ² ³

About 15% of patients with complete moles and less than 5% of those with partial moles develop gestational trophoblastic neoplasia, therefore, the monitoring of these women is fundamental to enable early detection of post-molar disease. The persistence of raised hCG levels and abnormal ultrasound imaging after uterine evacuation leads to the diagnosis of trophoblastic neoplasia, and in some cases metastasis may also be present.¹ ²

There is a choice between chemotherapy and/or surgery in the treatment of trophoblastic neoplasia, depending on staging, risk classification and reproductive desire. Patients with trophoblastic neoplasia are classified by the presence of risk factors according to the International Federation of Gynecology and Obstetrics' (FIGO) prognostic score (2002). Patients with a score from 0 to 6 are classified as having low-risk disease, receiving a single chemotherapy agent, whereas those with a score of 7 or more are considered as high-risk and benefit from receiving combination chemotherapy.²

More than 90% of patients with trophoblastic neoplasia undergo successful treatment with chemotherapy.² Thus, an additional concern is related to their reproductive future. A study by Matsui et al. (1997) showed that 46.8% of patients using etoposide in the treatment of trophoblastic neoplasia had impaired ovarian function.³ Cytotoxic drugs are potentially mutagenic and teratogenic, so there is also a concern about the adverse effects of the subsequent pregnancy. For example, methotrexate, which is used as a chemotherapy agent, inhibits the metabolism of folic acid, an essential vitamin in fetal development.⁶

In this review, we analyzed the studies existing in the literature that describe the reproductive future of patients with trophoblastic neoplasia treated with chemotherapy.

**METHOD**

The search was carried out by two independent researchers without any language restrictions in the following databases: Medline/Pubmed, Lilacs and the Cochrane Library. The keywords used in the searches (obtained using the Medical Subject Headings – MeSH) were “gestational trophoblastic disease” and “pregnancy outcome”.

The inclusion criteria used in this review were: studies that evaluated gestational rate and outcomes after chemotherapy treatment for gestational trophoblastic disease. There was no restriction on the time interval between treatment and pregnancy. All articles were written in English or Portuguese.

After reading the articles, the references of interest from the original studies were also included.

In the initial search, 163 articles were found, with 26 articles selected by reading the title and abstracts after being reviewed by two independent researchers. Eight articles were excluded because they related to case reports (two studies), articles written in Chinese, the same case series reported by another study, gestational trophoblastic neoplasia concomitant with current pregnancy, gestational prognosis after prophylactic chemotherapy during molar evacuation, pregnancy after chemotherapy associated with partial uterine resection and after uterine perforation. At last, 18 articles were included in this review.

The flow diagram for the selection of the articles can be found in Figure 1. No articles were found in the search on Cochrane and Lilacs.

**RESULTS**

The results of this study are summarized in Table 1, with the number of patients in each article included, as well as the number of pregnancies and their outcomes.

---

**FIGURE 1** Search mechanism and algorithm for selection of articles for the review.
Fertility
The articles did not show decreased fertility rates after treatment of the trophoblastic disease with chemotherapy.6-23

Time to pregnancy conception after the end of chemotherapy
Studies comparing pregnancies which were conceived within 6 months of the end of chemotherapy with those occurring after this period showed a higher spontaneous miscarriage rate in those who waited for a shorter time. Matsui et al. (2004) noted that the incidence of miscarriage, stillbirth and mole was higher in those conceiving within 6 months of the completion of chemotherapy compared to those who waited 1 year.17 Matsui et al. (2002) and Braga et al. (2009) also found that the incidence of miscarriage was higher in patients who became pregnant within 6 months.13,20 Lan et al. (2001) noted that patients presented a higher miscarriage rate when waiting 6.5±3.75

<table>
<thead>
<tr>
<th>Study</th>
<th>Patient (n)</th>
<th>Pregnancy (n)</th>
<th>Term [n (%)]</th>
<th>Stillbirth [n (%)]</th>
<th>Abortion and ectopic [n (%)]</th>
<th>Repeat mole [n (%)]</th>
<th>Preterm [n (%)]</th>
<th>Malformations [n (%)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rustin et al., 19847</td>
<td>245</td>
<td>368</td>
<td>273 (74.1)</td>
<td>8 (2.1)</td>
<td>55 (15)</td>
<td>-</td>
<td>5 (1.3)</td>
<td>2 (0.5)**</td>
</tr>
<tr>
<td>Song et al., 19888</td>
<td>205</td>
<td>355</td>
<td>279 (78.6)</td>
<td>5 (1.4)</td>
<td>28 (8)</td>
<td>-</td>
<td>20 (6.7)</td>
<td>3 (1)*</td>
</tr>
<tr>
<td>Kim et al., 19989</td>
<td>517</td>
<td>115</td>
<td>89 (77.4)</td>
<td>1 (0.9)</td>
<td>17 (15)</td>
<td>5 (4.3)</td>
<td>3 (2.6)</td>
<td>3 (3.2)*</td>
</tr>
<tr>
<td>Woolas et al., 19984</td>
<td>680</td>
<td>1,313</td>
<td>1,000 (76.2)</td>
<td>19 (1.4)</td>
<td>190 (14.5)</td>
<td>18 (1.4)</td>
<td>-</td>
<td>18 (1.7)*</td>
</tr>
<tr>
<td>Tuncer et al., 199910</td>
<td>43</td>
<td>29</td>
<td>22 (75.9)</td>
<td>-</td>
<td>3 (10.3)</td>
<td>1 (3.4)</td>
<td>3 (10.3)</td>
<td>1 (4.1)*</td>
</tr>
<tr>
<td>Amr et al., 199911</td>
<td>42</td>
<td>120</td>
<td>94 (78.3)</td>
<td>3 (2.5)</td>
<td>8 (6.8)</td>
<td>-</td>
<td>15 (12.5)</td>
<td>-</td>
</tr>
<tr>
<td>Lan et al., 200112</td>
<td>22</td>
<td>22</td>
<td>9 (40.9)</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
<td>-</td>
</tr>
<tr>
<td>Blagden et al., 200214</td>
<td>1,532</td>
<td>230</td>
<td>164 (71)</td>
<td>2 (1)</td>
<td>26 (11)</td>
<td>3 (1.3)</td>
<td>-</td>
<td>3 (1.3)**</td>
</tr>
<tr>
<td>Garner et al., 200215</td>
<td>-</td>
<td>581</td>
<td>393 (67.6)</td>
<td>9 (1.5)</td>
<td>106 (18)</td>
<td>8 (1.4)</td>
<td>35 (6)</td>
<td>10 (2.3)*</td>
</tr>
<tr>
<td>Matsui et al., 200213</td>
<td>129</td>
<td>243</td>
<td>169 (69.5)</td>
<td>2 (0.8)</td>
<td>27 (11.1)</td>
<td>5 (2.1)</td>
<td>5 (2.1)</td>
<td>-</td>
</tr>
<tr>
<td>Lok et al., 200316</td>
<td>50</td>
<td>21</td>
<td>16 (76)</td>
<td>-</td>
<td>2 (9)</td>
<td>-</td>
<td>2 (9)</td>
<td>2 (11)*</td>
</tr>
<tr>
<td>Matsui et al., 200417</td>
<td>137</td>
<td>258</td>
<td>180 (69.8)</td>
<td>3 (1.2)</td>
<td>29 (11.2)</td>
<td>5 (1.9)</td>
<td>5 (1.9)</td>
<td>-</td>
</tr>
<tr>
<td>Goto et al., 200418</td>
<td>50</td>
<td>43</td>
<td>34 (79)</td>
<td>0</td>
<td>4 (9.3)</td>
<td>0</td>
<td>0</td>
<td>3 (8.8)*</td>
</tr>
<tr>
<td>Garrett et al., 200819</td>
<td>-</td>
<td>631</td>
<td>422 (66.9)</td>
<td>9 (1.4)</td>
<td>7 (1.1)</td>
<td>9 (1.4)</td>
<td>42 (6.7)</td>
<td>10 (2.1)*</td>
</tr>
<tr>
<td>Braga et al., 200920</td>
<td>-</td>
<td>252</td>
<td>172 (68.2)</td>
<td>2 (0.8)</td>
<td>42 (16)</td>
<td>7 (2.8)</td>
<td>6 (2.4)</td>
<td>6 (2.4)**</td>
</tr>
<tr>
<td>Williams et al., 201421</td>
<td>1,204</td>
<td>255</td>
<td>174 (68.2)</td>
<td>2 (0.8)</td>
<td>34 (13.4)</td>
<td>3 (1.4)</td>
<td>14 (5.4)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>4,836</td>
<td>3,490 (72)</td>
<td>66 (1.4)</td>
<td>579 (12)</td>
<td>65 (1.6)</td>
<td>156 (4.7)</td>
<td>89 (2.3)**</td>
<td></td>
</tr>
</tbody>
</table>

*Number of malformations / delivery; **number of malformations / pregnancy.
months to conceive, while those who had an uneventful pregnancy showed an interval of 9.78±2.22 months between chemotherapy and pregnancy.12

**Single and multi agent chemotherapy**

Blagden et al. (2002) compared the pregnancy rates among women who conceived within a year of chemotherapy treatment with single or combined agent. The conception rate was higher in the single agent group. It was also noted that the miscarriage rate in the combination chemotherapy group was higher than the group treated with single agent. There was no difference in the rate of congenital anomalies, which was similar to the general population.14 However, Williams et al. (2014) compared the groups treated with single and combined agents and found no significant increase in the risk of miscarriage, ectopic pregnancy, repeat molar pregnancy or stillbirth, not even after comparing with the general population of the United Kingdom.21 Woolas et al. (1998) and Braga et al. (2008) also found no difference in the groups with single and combination chemotherapy.6,20

**Repeat molar pregnancy**

Woolas et al. (1998), Kim et al. (1998) and Lan et al. (2001) observed an increase in new molar pregnancy compared to the general population while analyzing the influence of chemotherapy on the reproductive future of patients with trophoblastic neoplasia.6,9,12 Matsui et al. (2002) showed a molar pregnancy recurrence rate that was seven times higher than the general population.13

**Higher stillborn rate**

Woolas et al. (1998), Garner et al. (2002), Garrett et al. (2008) and Vargas (2014) noted a higher stillbirth rate in patients treated with chemotherapy for gestational trophoblastic disease compared to the general population.6,15,19,22

**Higher malformation rate**

Only the study by Goto et al. (2004), which assessed choriocarcinoma patients treated with combination chemotherapy, noted a higher incidence of congenital anomalies.18

**Discussion**

The high cure rates of trophoblastic neoplasia after chemotherapy have enabled those patients to have a chance to conceive after the completion of the treatment. In the mid-1960s the mortality rate was 90%, whereas the current survival rate is 90 to 95%.19 However, due to the potential adverse effects of chemotherapeutic agents, the reproductive success rates as well as gestational complications have become a concern for these women.

The number of studies in the literature regarding this theme is still small. In general, most of them monitor the reproductive rates up to the first year after the end of treatment and the outcome of these pregnancies. All of studies found were retrospective.

The studies point out that there is no change in fertility. Most of the patients who wish to conceive end up doing so successfully. However, not all of the studies take into account the patient's desire to conceive.

It is advisable for patients to use birth control for at least 1 year after chemotherapy with negative hCG levels in order to enable them to safely become pregnant, since this is the time period when most relapses occur. The higher rate of miscarriage in the first 6 months after the end of treatment shown in the literature stresses the importance of not become pregnant around this period.12,13,17,20 In women who already experienced a failed pregnancy, another unsuccessful pregnancy can lead to negative psychological impact.

Four articles showed a higher prevalence of stillbirths in comparison to the general population.6,15,19,22 However, the etiology of this phenomena is still unknown, and it is important to increase clinical surveillance in these pregnancies.

Sebire et al. (2003) have shown a 20-fold increase chance (1 in 55 pregnancies) of another molar pregnancy in patients with prior hydatidiform mole.24 In this review, four studies showed an increased chance of a repeat hydatidiform mole in patients who underwent chemotherapy for gestational trophoblastic neoplasia.6,9,12,13 This event does not seem to be associated with chemotherapy itself, as the risk of presenting with another hydatidiform mole is higher even in patients with spontaneous regression of molar disease.

Only one study out of the four that compared single and combined agents found a difference between the two groups; showing that the conception rate was higher in the single agent group, and the miscarriage rate was higher in the combination group.14 The other three articles did not find any difference between the groups in relation to ectopic pregnancy, second molar pregnancy, miscarriage or stillbirth.6,20,21

Trophoblastic disease affects women, especially in the age group of 20 to 30 years. The data collected in the literature presents a small sample of studies. Nevertheless,
The results are homogeneous and comforting for those patients desiring motherhood. More studies with larger samples are necessary to ensure safer monitoring of patients with trophoblastic neoplasia who underwent chemotherapy.

**Conclusion**

The introduction of chemotherapy has changed the prognosis of patients with gestational trophoblastic neoplasia. Despite the new concern being the preservation of fertility, the studies did not show a decrease in fertility. The data is reassuring regarding pregnancies following chemotherapy. However, greater attention should be given to these patients, especially those who conceive within 6 months of treatment.

**References**


